tirzepatide higher dose trial for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity Weight reduction with different doses

Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimers disease: Study protocol for a randomised controlled trial (ELAD study)

How does FuturHealth compare to other GLP-1 providers

The funds investments will reportedly be focused on promising, innovative companies focused on advancing the specialty and who are aligned with the AAO strategic plan

The two primary pathways activated are the PI3K/Akt/mTOR pathway and the MAPK pathway

Stick around and Ill walk through how the two differ at the receptor level, what the clinical-trial data show on weight, blood sugar, and side effects, how they stack up on cholesterol and liver fat, and what that missing head-to-head really means

Zhang W, Drach J, Andreeff M , Deisseroth A